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ABSTRACT
Introduction: The potential immunoregulatory effects of
tocotrienols, the less studied form of vitamin E, had not been
determined for microglia until our last publication showcased
primary evidence of palm tocotrienols limiting microglia
activation, explicitly by inhibiting nitric oxide (NO) production.
Here we further explored the nitrite scavenging activity of the
two most potent NO-reducing tocotrienol isoforms - δ-
tocotrienol and Tocomin50% (contains a spectrum of
tocotrienols and α-tocopherol) based on their inhibitory effects
on NO production and also their effects on CD40 (a microglial
co-stimulator molecule) expression of BV2 microglia. Methods:
BV2 cells were treated with two different doses of tocotrienols
(δ-tocotrienol: 3.96 μg/mL and 19.80 μg/mL; Tocomin50%:
47.50 μg/mL and 237.50 μg/mL) followed by stimulation with 1
μg/mL of lipopolysaccharide (LPS). A chemical scavenging
assay was conducted to study the nitrite scavenging activity of δ-
tocotrienol. Together with Tocomin50%, we also determined
their effects on CD40 expression of BV2 microglia via flow
cytometry. Results: We demonstrate that the inhibitory effect of
tocotrienols on NO production by microglia is not attributed to
their nitrite scavenging activity. Additionally, tocotrienols also
reduced the expression of the microglial co-stimulator molecule,
CD40. Conclusions: Our data aids the further characterisation
of the actions of tocotrienols on microglia, offering insight into
the potential modulatory properties of palm tocotrienols on
microglial inflammatory responses within the central nervous
system (CNS).
Keywords: Microglia, Palm tocotrienols,
Lipopolysaccharide, Nitric oxide, CD40, Inflammation
INTRODUCTION
Microglia are central nervous system (CNS)-specific
macrophages. They derive from primitive myeloid progenitors
that migrate to the brain from the yolk sac during early-stage
development (1). With concerted movements, microglia are able
to monitor the entire brain every few hours (2) screening for
dead and damaged neurones, invading microorganisms, and
endogenous disease proteins (3). In response to various types of
insults, they assume a pro-inflammatory phenotype by
proliferating, changing from ramified to amoeboid morphology
and secreting pro-inflammatory mediators such as cytokines,
chemokines, reactive oxygen and nitrogen species as well as
perform phagocytic activity. These responses are collectively
described as microgliosis and is primarily elicited for the
beneficial purpose of resolving a CNS insult (4). However,
studies show that these responses of microglia can cause
detrimental effects to the CNS microenvironment (5-7) and play
a key role in the pathogenesis and progression of
neurodegenerative diseases (1). 
Vitamin E is found in edible oils and abundantly in palm oil and
is a potent antioxidant with anti-inflammatory properties (8-10).
Natural vitamin E consists of two closely related compounds –
tocopherols and tocotrienols. Both comprise of 4 chemically
distinct isoforms and are further assigned as alpha (α-), beta (β),
gamma (γ-) and delta (δ-). They differ from tocopherols by
having an unsaturated farnesyl isoprenoid tail attached to a
chroman ring structure (Figure 1) (11). Tocotrienols were much
less studied until they were discovered to have better
ameliorative effects than tocopherols in cancer (12, 13) and CNS
injury paradigms (14). They appear to be more neuroprotective
than tocopherols (14), have better antioxidant properties (15),
more  efficient  tissue  penetration  and  higher  bioavailability
in  vital  organs compared to tocopherols (16). For example,
nanomolar concentrations of α-tocotrienol, but not α-
tocopherol, are sufficient to rescue neurones from cell death
from various types of insults (14, 17). The concerns of
tocotrienols’ bioavailability in the CNS were addressed by
several studies that demonstrated tocotrienols are detectable in
the brain and spinal cord of orally supplemented rats (18-20) and
even in human brains (21).
A number of studies have reported the anti-inflammatory effects
of tocotrienols on macrophages (22, 23) as well as tocopherols
on microglia (8, 9). However, no study has explored the effects
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of tocotrienols on microglia until our last publication which
showcased the first evidence on potential immunoregulatory
effects of tocotrienols by limiting nitric oxide (NO) production
of microglia (24). The present study was thus undertaken to
explore the nitrite scavenging ability of the most potent
tocotrienols fragment, delta-(δ-) tocotrienol. Together with
Tocomin50% (a complex of tocopherols and tocotrienols), we
study their effects on CD40 (a microglial activation marker)
expression of the BV2 microglia cell line, using an in vitro
model of microgliosis stimulated with the bacterial endotoxin,
lipopolysaccharide (LPS).
MATERIALS AND METHODS
Culture of the BV2 murine microglia cell line
BV2 cells are microglia immortalised with a v-raf/v-myc
oncogene (25). Cells were maintained in Dulbecco Modiﬁed
Eagle medium (DMEM) supplemented with 5% heat-inactivated
foetal bovine serum (FBS), 100 U/mL penicillin, 100 μg/mL
streptomycin, 1 mL/L gentamicin, 250 μg/mL fungizone (all
Invitrogen, Carlsbad, CA, USA), 1X non-essential amino acids
(Thermo Fisher Scientific, Waltham, MA, USA), 2 mg/mL
insulin (Thermo Fisher Scientific, Waltham, MA, USA) and 1.5
g/L sodium bicarbonate (Thermo Fisher Scientific, Waltham,
MA, USA) (supplemented DMEM). Cultures were maintained
at 37°C with 95% humidified air and 5% CO2. Cells were
harvested upon reaching 80-90% confluence by treating with
0.25% trypsin in 1 mM EDTA for 5 mins at 37°C and used for
downstream experiments. BV2 cells were activated with 1
μg/mL LPS (E. coli serotype O26:B6; Sigma-Aldrich, St. Louis,
MO, USA; Cat. No. L2762). LPS was reconstituted with 1× PBS
and diluted to working concentrations of 1 μg/mL with
supplemented DMEM.
Palm tocotrienols treatment
δ-tocotrienol and Tocomin50% (1 g of Tocomin50% typically
contains 115 mg α-tocotrienol, 15 mg β-tocotrienol, 210 mg γ-
tocotrienol and 55 mg δ-tocotrienol and 115 mg α-tocopherol)
were generous gifts from ExcelVite Sdn. Bhd. (Ipoh, Malaysia).
Stock solutions of δ-tocotrienol and Tocomin50% were
prepared in ethanol and diluted to working concentrations with
supplemented DMEM. Two different concentrations of δ-
tocotrienol (3.96 μg/mL; 19.8 μg/mL) and Tocomin50% (47.50
μg/mL; 237.50 μg/mL) were added to cultures 24 hrs before
stimulation with 1 μg/ml LPS for 24 hrs.
Determination of nitrite scavenging activity
A chemical scavenging assay was conducted to determine
whether δ-tocotrienol was scavenging nitrite released in the
culture medium. Briefly, 50 μL of serial diluted δ-tocotrienol
was pipetted into a 96-well plate in triplicates. Next, 50 μL of 20
mM SNP (sodium nitroprusside; a NO donor; Sigma-Aldrich,
St. Louis, MO, USA) dissolved in PBS (10 mM final
concentration) was added to each well and the plate was
incubated at room temperature for 150 mins. Negative controls
for this experiment were wells with culture medium only while
the nitrite scavenger PTIO (2-Phenyl-4,4,5,5-
tetramethylimidazoline-1-oxyl 3-oxide; Sigma-Aldrich, St.
Louis, MO, USA) was used as a positive control. Following
incubation, an equal amount of Griess reagent (1%
sulphanilamide/0.1% N-1-napthylethylenediamine
dihydrochloride/2.5% phosphoric acid; all Sigma-Aldrich, St.
Louis, MO, USA) was added to each well in order to determine
the nitrite content. Absorbance was read at 530 nm (Dynex
MRX II microplate reader; Dynex Technologies Inc., Chantilly,
VA, USA) after 10 mins incubation period at room temperature.
NO2- concentration was calculated following deduction of
background (culture media; supplemented DMEM without
phenol red), with reference to a standard curve generated by
serially-diluted sodium nitrite (see Supplementary Figure 1).
Immunophenotyping of CD40 expression with flow
cytometry
Expression of the microglial activation marker CD40 was
assessed by flow cytometry. Briefly, 1.5 x 105 BV2 cells were
seeded into 25 cm2 tissue culture flasks and treated with
tocotrienols (refer to section 2.3), followed by stimulation with
LPS for 48 hrs. Cells were then harvested, washed with 0.1%
BSA/PBS and incubated with CD40-FITC antibody (BD; Cat
No. 553723; 10 μg/mL per 5.0 x 105 of cells) for 20 mins at 4˚C.
After incubation, cells were resuspended in 0.1% BSA/PBS and
further analysed with the BD LSRFortessaTM flow cytometer
(BD Biosciences, San Jose, CA, USA).  Ten thousand gated
events were recorded. Data were analysed using BD FACS
DivaTM software. The gating was determined based on
appropriate isotype-stained control (FITC IgG2a, κ isotype
control; BD; Cat No. 553929). An unstained sample was
prepared to reveal cellular autofluorescence in order to eliminate
it as background.
Statistical analysis
Significance was assessed using one-way analysis of variance
(ANOVA), followed by the Tukey’s post hoc test, using
GraphPad Prism version 5 (GraphPad software, La Jolla, CA,
USA).
RESULTS
Following our previous report which showcased the inhibitory
ability of palm-tocotrienols on nitric oxide (NO) production by
BV2 microglia (24), in this study, we further investigated the
nitrite scavenging activity of δ-tocotrienol. Together with
Tocomin50% (a tocotrienol/ tocopherol complex), we also
explored their effects on CD40 microglial activation marker
expression. The tocotrienol fractions and dosages tested in this
study had previously been shown by us to best inhibit NO
production by BV2 cells (24). Ethanol (EtOH; 0.1%) was used
as a diluent control. A set of data from the Griess assay which
was conducted to reconfirm the inhibitory effects of selected
dosage of tocotrienols on NO production by BV2 microglia cells
is included as a supplementary figure (Supplementary Figure 2).
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δ-tocotrienol does not scavenge NO
A nitrite scavenging assay was conducted by introducing a
nitrite producer SNP (sodium nitroprusside) into wells
containing serially diluted δ-tocotrienol. PTIO (10μM), a
commercial NO scavenger was included as a positive control.
PTIO scavenged NO by 31.5 ± 8.5% (Figure 2; p<.05).
However, none of the δ-tocotrienol doses tested reduced NO
levels. Therefore, δ-tocotrienol does not inhibit NO production
of microglia via nitrite scavenging.
δ-tocotrienol and Tocomin50% treatment limited CD40
expression in both unstimulated and LPS-stimulated BV2
cells
CD40 is a co-stimulatory marker which is upregulated during
microglial activation (26). Therefore, effects of δ-tocotrienol and
Tocomin50% on the expression of CD40 on BV2 cells were
determined using immunophenotyping via flow cytometry. The
number of CD40+ BV2 cells increased from 23.5% to 96.8%
following 48 hrs of LPS stimulation (Figure 3). Both δ-
tocotrienol and Tocomin50% reduced the number of CD40+
LPS-stimulated BV2 microglia. The highest reduction in CD40+
cells was conferred by 19.80 μg/mL δ-tocotrienol and 237.50
μg/mL of Tocomin50%, reducing CD40+ cells to 85.7% and
73.9% accordingly compared to LPS-stimulated BV2 cells.
Using the median fluorescence intensity (MFI) readouts from the
flow cytometer, effects of tocotrienols on the intensity of CD40
expression levels by BV2 cells was determined. Figure 4 shows
that not only do the number of CD40+ BV2 cells reduce
following δ-tocotrienol and Tocomin50% treatment (at both
doses), but the levels of their CD40 expression per cell is also
limited. 237.5 μg/mL of Tocomin50% limited CD40 expression
of BV2 cells by 49.1% significantly (Figure 4; p<.05). These
results reveal that tocotrienols are not only capable of limiting
the number of BV2 microglia cells from acquiring CD40
expression but can also limit the degree of CD40 expression per
cell.  
DISCUSSION
We have demonstrated the regulatory activities of palm
tocotrienols in an in vitro model of microgliosis by examining
their scavenging ability of nitrite and their effects on BV2
microglia cells’ CD40 expression. From our previous work, the
two most effective tocotrienol fragments in reducing nitric oxide
(NO) production: δ-tocotrienol and Tocomin50% (a
tocopherol/tocotrienol mixture) and their respective potent doses
(24) were chosen to further explore their potential in modulating
microglial responses here. The tocotrienols tested previously
were α-and γ-tocotrienol.
Nitric  oxide  (NO)  produced  by  microglia  during
inflammation is  known  to  be  harmful  to neurones (27). It has
been attributed to the detrimental effects of various
neurodegenerative diseases, including neuronal death in
Alzheimer’s disease (28),  Parkinson’s disease (29),
demyelination  in  multiple  sclerosis (30), HIV-associated
dementia (31) as well as traumatic brain injury (32). It was
hypothesised that tocotrienols would limit production of NO by
Figure 1: The chemical structure of tocotrienols includes a head (chroman
ring) with an active hydroxyl group and an unsaturated farnesyl tail. α-
tocotrienol has three methyl groups on the chroman ring, γ-tocotrienol has
two and δ-tocotrienol only one (adapted from(48)).
Supplementary Figure 1: A representative standard linear curve generated
from the Griess assay by plotting absorbance values (optical density; OD)
against serial dilutions of sodium nitrite (NaNO2).
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Figure 2: Reduced NO production by δ-tocotrienol is not due to nitrite
scavenging. Graph depicts percentage of nitrite accumulation produced by
SNP in the presence or absence of δ-tocotrienol or PTIO for 150 mins.
Results are expressed in mean of % ± SD of four independent experiments.
*p<0.05 compared to media only group; One-way ANOVA with Tukey’s
post hoc test. SNP, sodium nitroprusside; PTIO, 2-Phenyl-4,4,5,5-
tetramethylimidazoline-1-oxyl 3-oxide; EtOH 0.1%, ethanol 0.1%.
Supplementary Figure 2: (A) δ-tocotrienol and Tocomin50% reduced NO
production by LPS-stimulated BV2 cells. 5.0 x 104 BV2 cells were seeded
in 96-well plates and incubated with 2 different doses of δ-tocotrienol or
Tocomin50% for 24 hrs. Nitrite concentration was determined using
Griess assay at 18, 24 and 48 hrs following stimulation with 1 μg/mL of
LPS. The control group consisted of untreated LPS-stimulated BV2 cells.
(B) δ-tocotrienol and Tocomin50% did not affect cell viability of BV2
cells. Viability of BV2 cells were assessed at 48 hrs post LPS-stimulation
using the MTS assay. The control group consisted of untreated LPS-
stimulated and unstimulated group. Results are expressed in mean ± SD of
3 independent experiments.*p<.05 compared to respective control groups.
#p<.05 compared to untreated unstimulated groups. NO2-, nitrite; MTS, 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl-
2H-tetrazolium;LPS, lipopolysaccharide; L-NAME, N-nitro-L-arginine
methyl ester; EtOH 0.1%, ethanol 0.1%; SD, standard deviation.
Figure 3: Both δ-tocotrienol and Tocomin50% treatment reduce CD40
expression in LPS-stimulated BV2 microglia. BV2 cells were treated with
tocotrienols for 24 hrs and CD40 expression of the cells were acquired 48
hrs post-LPS stimulation by immunophenotyping via flow cytometry.
Density plots show CD40 expression of BV2 cells alone (control group)
and BV2 treated with different doses of δ-tocotrienol and Tocomin50%.
Numbers within the upper right region of plots indicate percentage of
CD40+ cells. Results are expressed in percentage and are representative of
2 independent experiments. 
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microglia as they have been shown to inhibit other pro-
inflammatory mediators such as TNF-α by macrophages (33).
Notably, there was no literature on effects of tocotrienols on
microglia NO production until our last publication which
showcased the inhibitory effects of tocotrienols in limiting
microglia NO production without affecting the cell viability
(24).
Here, in order to understand the mechanism of the NO inhibitory
effects of tocotrienols, we subjected δ-tocotrienol to a chemical
NO-producing system to determine their NO scavenging
activity. Unlike other natural products and their derivatives
which react as strong NO scavengers such as green tea (34),
curcumin (35, 36) and extracts from medicinal plants (37),
tocotrienols do not possess the similar ability. Therefore, δ-
tocotrienols do not reduce the NO levels by scavenging the
extracellular nitrite in the culture medium. Further work is
underway to assess the effects of palm tocotrienols upon the key
enzyme in this paradigm, the inducible nitric oxide synthase
(iNOS) as will assist us to understand its underlying mechanism
of action on NO production by microglia.
CD40 is a co-stimulatory molecule which is expressed by a wide
variety of antigen presenting cells (APCs) including microglia
(38). It is a member of the tumour necrosis factor-R (TNF-R)
family and this co-stimulatory molecule plays a crucial role in
activation of APCs (38, 39). Microglia express low amount of
MHC-class II, CD86 (B7) as well as CD40 within a healthy CNS
(40, 41). Increased expression of CD40 on microglia has been
described in various types of neurodegenerative diseases
including multiple sclerosis (42), experimental allergic
encephalomyelitis (EAE) (42) and Alzheimer’s disease (43).
Following formation of MHC II/TCR complex, ligation of CD40
with CD40 ligand (CD40-L or CD154) on the surface of T cell
serves as the secondary signal to further augment the level of
APCs’ activation (39, 41). It has also been revealed that ligation
of CD40 on microglia increases production of NO (44) and
TNF-α (45, 46) in the presence of IFNγ. Although CD40 ligation
alone does not induce the production of these inflammatory
mediators, the augmentation effect rendered by CD40 does
contribute to tissue damage as studies have shown that CNS
diseases such as multiple sclerosis and Alzheimer’s disease can
be ameliorated by blocking the interaction between CD40 and
CD40L (38).
Here, we demonstrated that δ-tocotrienol and Tocomin50%
were able to reduce the number of CD40-expressing (CD40+)
cells in both unstimulated and the LPS-stimulated group at the
higher doses tested. It is worth mentioning that this is the first
report on inhibition of microglial CD40 expression by
tocotrienols. An intriguing study with the experimental
autoimmune encephalomyelitis (EAE) model of multiple
sclerosis showed that CD40 expression  by  microglial  was
needed  for  their  complete  activation  during  CNS
autoimmune inflammation (41). It is the fully activated
microglia  which  acts  as  an  APC  and  present  antigens  to  T
cells  and stimulates the subsequent inflammatory process.
Therefore, by reducing microglial CD40 expression, it  can  be
assumed  that palm tocotrienols, especially the Tocomin50%
complex,  may  be  able  to  prevent  full activation of microglia
by preventing the ligation with  T  cells via MHC II-TCR and
CD40-CD40L interactions. Activated microglia  have also been
implicated in contributing to Th1 responses by inducing naïve T
cell proliferation and differentiation into Th1, leading to CNS
inflammation and tissue damage (47). Thus, reduction of CD40
expression in microglia may lessen microglial activation  and
this  can result  in  reduced  T  cell  activation  which  is
suggested to subsequently hamper inflammatory activities
within CNS.
Interestingly, we have demonstrated that δ-tocotrienol and
Tocomin50% exert their anti-inflammatory effects
differentially on microglia responses. Here, δ-tocotrienol was
shown better for downregulating NO (Supplementary 2A) while
Tocomin50% performed better in reducing CD40 expression by
microglia. Therefore both fractions tested have their own
Figure 4: Both δ-tocotrienol and Tocomin50% treatment reduce CD40 median fluorescence intensity (MFI) of LPS-stimulated BV2 microglia. Histograms
show MFI of CD40+ cells. Data are mean ± SD from two independent experiments. #p<.05 compared to unstimulated control group. *p<.05 compared to LPS-
stimulated control group; One-way ANOVA with Tukey’s post hoc test.
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limiting properties on microglia activation and determining
which is better for alleviating CNS inflammation is best tested in
an animal model.
CONCLUSION
Our results provide novel insight into the role of palm
tocotrienols in modulating microglia responses. This may offer a
potential therapeutic focus for neurodegenerative and
neuroinflammatory diseases by palm tocotrienols. To dissect the
immunomodulatory mechanisms of tocotrienols we aim to next
study the expression of inducible nitric oxide synthase (iNOS) to
determine whether tocotrienols modulate this enzyme to reduce
NO production. We will also examine the NFκB signalling
pathway that is key for induction of inflammatory responses, and
CD80/86 expression to examine potential T cell responses.
Further investigation is also warranted to best harness the
immunomodulatory potential of tocotrienols in the paradigm of
neuroinflammation.
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